Novel Psychedelic Molecule Shows Promise in Pre-Clinical Cocaine Addiction Treatment Trial
Complete the form below and we will email you a PDF version of "Novel Psychedelic Molecule Shows Promise in Pre-Clinical Cocaine Addiction Treatment Trial "
Clearmind Medicine has announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
"This exciting research on MEAI could go a long way in helping those who need it," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.”
The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference (CPP*) model.
Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study.
The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.
"Once again, MEAI has shown the potential to become a game changer in the field of addiction treatments" Zuloff- Shani added. "We intend to further explore the potential of MEAI as an anti-cocaine addiction treatment."